The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment

Ferretti, Elisa; Corcione, Anna; Pistoia, Vito

doi:10.1189/jlb.3mr0117-033r

Cited by 61 publications

(44 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PI3K overexpression is an oncogenic factor in squamous cell carcinomas and is considered to be a therapeutic target (19). Interestingly, the cytokine IL-31R was found to be involved with the PI3K/AKT pathway in relation to the pathogenesis of intense pruritis among MF/SS patients (20,21). Furthermore, AKT activation as a proxy for hyperproliferation and growth was more often found in SS skin cells than in circulating SS cells, suggesting a molecular pathogenesis of cutaneous manifestations (22).…”

Section: Discussionmentioning

confidence: 99%

New Insights Into the Complex Mutational Landscape of Sézary Syndrome

et al. 2020

View full text Add to dashboard Cite

Sézary syndrome (SS) is a genetically and clinically distinct entity among cutaneous T-cell lymphomas (CTCL). SS is characterized by more aggressive disease compared to the most common indolent type of CTCL, mycosis fungoides. However, there are limited available genomic data regarding SS. To characterize and expand current mappings of the genomic landscape of CTCL, whole exome sequencing (WES) was performed on peripheral blood samples from seven patients with SS. We detected 21,784 variants, of which 21,140 were novel and 644 were previously described. Filtering revealed 551 nonsynonymous variants among 525 mutated genes−25 recurrent mutations and 1 recurrent variant. Several recurrently mutated genes crucial to pathogenesis pathways, including Janus kinase (JAK)/signal transducers and activators of transcription (STAT), peroxisome proliferator-activated receptors (PPAR), PI3K-serine/threonine protein kinases (AKT), and fibroblast growth factor receptors (FGFR), were identified. Furthermore, genetic mutations spanned both known and novel genes, supporting the idea of a long-tail distribution of mutations in lymphoma. Acknowledging these genetic variants and their affected pathways may inspire future targeted therapies. WES of a limited number of SS patients revealed both novel findings and corroborated complexities of the "long-tail" distribution of previously reported mutations.

show abstract

Section: Discussionmentioning

confidence: 99%

New Insights Into the Complex Mutational Landscape of Sézary Syndrome

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Interleukin-31 (h), 162,224 Oncostatin M (h) 163 IL-31Rα, OSMR (e.n.r.) but anticipated IL-31 (e.n.r.)…”

Section: Agonist Receptor Agonist Receptormentioning

confidence: 99%

Role of mast cells and basophils in pruritus

Steinhoff

Buddenkotte

Lerner

2018

Immunological Reviews

View full text Add to dashboard Cite

To protect our body systems, there is a constant interactive conversation between the skin nervous and immune system. Important elements of this conversation in the skin include mast cells, basophils, and sensory nerve fibers. These cells employ a vast array of sensors that detect danger and react accordingly. This reaction, summarized as neurogenic inflammation, manifests at the conscious level as sensations including pain and itch. Here we provide a perspective on the blossoming knowledge that is illuminating connections between mast cells, basophils, and sensory nerve fibers in the mediation of itch. We discuss established mediators and receptors, in particular cytokine and neuropeptide pathways, upstream proteases, and proteinase-activated receptors, and the emerging role of mas-related G-protein-coupled receptors in itch.

show abstract

“…Interleukin 31 is primarily produced by Th2 lymphocytes and is associated with pruritus in atopic dermatitis. Besides mast cells, tumor cells (T‐ and B‐cell lymphoma, myeloproliferative disorders) also secrete IL31 .…”

Section: Symptomsmentioning

confidence: 99%

Mastocytosis – pathogenesis, clinical manifestation and treatment

Wagner¹,

Staubach

2018

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary The term mastocytosis designates a group of rare disorders characterized by typical skin lesions, frequently associated episodes of anaphylaxis, and clinical symptoms related to the release of various mediators. Dermatologists/allergists are frequently the first to establish the diagnosis. The condition is based on clonal mast cell proliferation, usually in the skin or bone marrow and only rarely in the gastrointestinal tract or other tissues. In general, mastocytosis has a good prognosis in terms of life expectancy. Rare variants – including mast cell leukemia, aggressive mastocytosis, and the exceedingly rare mast cell sarcoma – require cytoreductive therapy. In cases associated with hematological neoplasms, the prognosis depends on the underlying hematologic disorder.

show abstract

The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment

Cited by 61 publications

References 53 publications

New Insights Into the Complex Mutational Landscape of Sézary Syndrome

New Insights Into the Complex Mutational Landscape of Sézary Syndrome

Role of mast cells and basophils in pruritus

Mastocytosis – pathogenesis, clinical manifestation and treatment

Contact Info

Product

Resources

About